# Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells

> **NCT04224207** · PHASE3 · COMPLETED · sponsor: **Ankara Universitesi Teknokent** · enrollment: 32 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Inherited Retinal Dystrophy

## Interventions

- **BIOLOGICAL:** Wharton's jelly derived mesenchymal stem cell

## Key facts

- **NCT ID:** NCT04224207
- **Lead sponsor:** Ankara Universitesi Teknokent
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2019-10-30
- **Final completion:** 2020-01-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04224207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04224207, "Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04224207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*